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Abstract
Background: Evidence suggests a confounding effect of mismatch repair (MMR) status on immune response in colorectal
cancer. The identification of innate and adaptive immune cells, that can complement the established prognostic effect of
CD8 in MMR-proficient colorectal cancers patients, representing 85% of all cases, has not been performed.
Methodology/Principal Findings: Colorectal cancers from a test (n=1197) and external validation (n=209) cohort of MMR-
proficient colorectal cancers were mounted onto single and multiple punch tissue microarrays. Immunohistochemical
quantification (score 0-3) was performed for CD3, CD4, CD8, CD45RO, CD68, CD163, FoxP3, GranzymeB, iNOS, mast cell
tryptase, MUM1, PD1 and TIA-1 tumor-infiltrating (TILs) reactive cells. Coexpression experiments on fresh colorectal cancer
specimens using specific cell population markers were performed. In the test group, higher numbers of CD3+ (p,0.001),
CD4+ (p=0.029), CD8+ (p,0.001), CD45RO+ (p=0.048), FoxP3+ (p,0.001), GranzymeB+ (p,0.001), iNOS+ (p=0.035),
MUM1+ (p=0.014), PD1+ (p=0.034) and TIA-1+ TILs (p,0.001) were linked to favourable outcome. Adjusting for age,
gender, TNM stage and post-operative therapy, higher CD8+ (p,0.001; HR (95%CI): 0.66 (0.64-0.68)) and TIA-1+ (p,0.001;
HR (95%CI): 0.56 (0.5-0.6)) were independent prognostic factors. Moreover, among patients with CD8+ infiltrates, TIA-1
further stratified 355 (35.6%) patients into prognostic subgroups (p,0.001; HR (95%CI): 0.89 (95%CI: 0.8-0.9)). Results were
confirmed on the validation cohort (p=0.006). TIA-1+ cells were mostly CD8+ (57%), but also stained for TCRcd (22%),
CD66b (13%) and only rarely for CD4+, macrophage and NK cell markers.
Conclusions: TIA-1 adds prognostic information to TNM stage and adjuvant therapy in MMR-proficient colorectal cancer
patients. The prognostic effect of CD8+ TILs is confounded by the presence of TIA-1+ which translates into improved risk
stratification for approximately 35% of all patients with MMR-proficient colorectal cancers.
Citation: Zlobec I, Karamitopoulou E, Terracciano L, Piscuoglio S, Iezzi G, et al. (2010) TIA-1 Cytotoxic Granule-Associated RNA Binding Protein Improves the
Prognostic Performance of CD8 in Mismatch Repair-Proficient Colorectal Cancer. PLoS ONE 5(12): e14282. doi:10.1371/journal.pone.0014282
Editor: Alfons Navarro, University of Barcelona, Spain
Received June 3, 2010; Accepted November 16, 2010; Published December 10, 2010
Copyright:  2010 Zlobec et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors were funded by the Institute for Pathology, University Hospital of Basel, Research pool account. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: izlobec@uhbs.ch
Introduction
The prognosis of patients with colorectal cancer can be viewed
as an interaction between tumor- and host-related factors [1].
Experimental evidence over the last 20 years provides support for
the concept of immunosurveilllance in cancer, implicating both
innate and adaptive immune responses [2]. In colorectal cancer,
CD3, CD4, CD8, CD20, Granzyme B, and FoxP3+ tumor
infiltrating lymphocytes (TILs) have been identified as potential
indicators of outcome, while the identification of cytotoxic T-
lymphocytes, mast cells and dendritic cells as elicitors of anti-
tumor responses has underlined new avenues for potential
immunotherapies [3,4,5].
In colorectal cancer, the balance between host- and tumor-
related factors is exemplified by mismatch repair (MMR)-deficient
sporadic cases, accounting for approximately 15% of all tumors
and characterized by defective MMR machinery [6]. Patients with
these MMR-deficient cancers are described as having abundant
CD8+ cytotoxic T-cell infiltrate [7] and are often linked to more
‘‘favourable’’ tumor-related features, namely the presence of a
pushing tumor border configuration, the presence of a distinctive
band of peritumoral lymphocytic inflammation and little tumor
budding, the latter a histomorphological hallmark of epithelial
mesenchymal transition [8]. This phenotypic constellation, by
‘‘tipping the scale’’ in favour of a strong defence may in part be
responsible for the more favourable overall prognosis of patients
with MMR-deficient compared to MMR-proficient tumors [9].
Interestingly, despite the known confounding effect of MMR status
on immunological responses in colorectal cancer, comprehensive
analyses of cell types involved in immune response and
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MMR-proficient cancers, encompassing 85% of all colorectal
cancer cases.
Therefore, the aim of this study was to determine the additional
prognostic benefit, over the performance of CD8 alone, of 12
tissue-based immunologic biomarkers in MMR-proficient colo-
rectal cancer patients. These protein markers including CD3,
CD4, CD45RO, CD68, CD163, FoxP3, GranzymeB, iNOS, mast
cell tryptase, MUM1p, PD1 and TIA-1 were specifically selected
to cover the widest range of possible cell types involved in innate
and adaptive immune responses. This was accomplished using an
initial test group of 1197 patients and an external validation cohort
of 209 patients, respectively with complete clinico-pathological
and follow-up data.
Methods
Ethics Statement
Written consent has been given from the patients for their
information to be stored in the hospital database and used for
research. The use of tissue was approved by the corresponding
Ethics Committees of the University Hospital of Basel and
University of Athens. Freshly excised clinical specimens included
in this study were collected from consenting patients undergoing
surgical treatment at Basel University Hospital.
Test Group
Patients and specimen characteristics. 1420 primary pre-
operativelyuntreated,unselectedsporadiccolorectalcancerpatients
treated at the University Hospital of Basel between the years 1987
and 1996 were included in this study. Haematoxylin and eosin
(H&E) stained slides were reviewed by an experienced
gastrointestinal pathologist (L.T.) and clinical data were retrieved
from patient records, where available. Clinical outcome of interest
was cancer-specific survival time. A tissue microarray of these 1420
patients was constructed. From each patient, one representative
tumor block was punched using a tissue cylinder 0.6 mm in
diameter. Tissue was brought into one recipient paraffin block
(362.5 cm) using a homemade semi-automated tissue arrayer. 57
tissues from normal colorectal mucosa were included as a control.
Assay Methods. The tissue microarray was immunostained
for 13 immunological protein markers and mismatch repair
markers. Protocols for MLH1, MSH2, MSH6, CD8 and FoxP3
have been described elsewhere [10]. Briefly, the remaining
protocols were carried out as follow: CD163; NeoMarkers, MS-
1103, monoclonal, 1:40, Citrate buffer pH6, 100uC, 309; CD20;
Dako, M0755, monoclonal, 1:50 Citrate buffer pH6, 100uC, 309;
CD4; NeoMarkers, MS-1528, monoclonal, 1:40, Citrate buffer
pH6, 100uC, 609; CD68; Dako, M0876, monoclonal, 1:200,
Citrate buffer pH6, 100uC, 159; GranzymeB; Novocastra, NCL-L-
GRAN-B, 1:10, Citrate buffer pH6, 120uC, 109, iNos; Abcam,
ab15323, polyclonal, 1:100 ER1 buffer, 209, Mast cell tryptase;
Dako, M7052, monoclonal, 1:2000, no retrieval; Mum1; Dako,
M7259, monoclonal, 1:50, Citrate buffer pH6, 100uC, 309; PD1;
R&D Systems, AF1086, monoclonal 1:40 Citrate buffer pH6,
120uC, 109; TIA-1; Immunotech, IM2550, monoclonal, 1:250, no
retrieval; CD3; Dako, monoclonal, Citrate buffer; 1:50; and
CD45RO; Thermo Scientific UCHL-1, monoclonal, Citrate
buffer, 1:500. Negative control tissues were tested and
underwent the same protocol with the primary antibody omitted.
Protein markers were scored by three observers (A.L., S.P.,
A.T.) by analyzing the number of positive cells per tissue
microarray punch. No image analysis software was used. The
total number of immunoreactive cells within the tumor microen-
vironment was evaluated, independent of localization (intratu-
moral or stromal). The total number of cells per tissue microarray
punch were given scores of 0 when no positive cells were present,
and scores 1, 2 and 3 when 1-10 positive cells, 11-50 positive cells
and .50 positive cells per punch could be observed, respectively.
For PD1 and iNOS, cases were scored as the complete absence or
presence of any positive cells.
Validation Group
221 unselected, non-consecutive colorectal cancer patients
treated at the Attikon University Hospital, University of Athens,
Greece between the years 2004 and 2006 were included as an
independent validation group. H&E slides were reviewed and
clinical data retrieved from patient records (Table 1). Clinical
outcome of interest was cancer-specific survival time. A tissue
microarray of primary colorectal cancer resections from these 221
patients was constructed. In order to exclude bias due to possible
tumor heterogeneity, each patient had multiple tissue and tumor
punches taken from formalin-fixed, paraffin-embedded blocks using
a tissue cylinder with a diameter of 0.6 mm which were
subsequently transferred into one recipient paraffin block using a
homemade semiautomated tissue arrayer. Each patient had an
average of 4 tumor punches included on the area, including 2 from
the tumor center and 2 from the invasive front. Immunohisto-
chemistry was performed for the tissue microarray according to the
Table 1. Characteristics of patients with mismatch repair-
proficient colorectal cancer.
Features Frequency n (%)
Test Group
(n=1197)
Validation
Group (n=209)
Age (yrs) Mean, range 71 (30-96) 71N0, 35-93
Gender Female 596 (50.0) 101 (50N5)
Male 595 (50.0) 99 (49N5)
Tumor location Left-sided 383 (32.5) 124 (62N0)
Right-sided 343 (29.1) 48 (24N0)
Rectum 451 (38.3) 28 (14N0)
Histologic subtype Mucinous 89 (7.4) 25 (12N5)
Non-mucinous 1108 (92.6) 175 (87N5)
pT classification pT1-2 249 (21.4) 49 (24N5)
pT3-4 916 (78.6) 151 (75N5)
pN classification pN0 587 (51.4) 101 (50N5)
pN1-2 555 (48.6) 99 (49N5)
Tumor grade G1-2 1037 (89.1) 121 (75N7)
G3 128 (11.0) 39 (24N4)
Vascular invasion Absent 834 (71.5) 168 (81N9)
Present 332 (28.5) 37 (18N1)
Local recurrence Absent 208 (55.2) -
Present 169 (44.8)
Distant metastasis Absent 313 (80.9) 183 (90N6)
Present 74 (19.1) 19 (9N4)
Post-operative
therapy
None 289 (76.7) 72 (35N1)
Treated 88 (23.3) 133 (64N9)
Median (months) Rate (95%CI) 73.0 (63-85) 58.0 (48-65)
doi:10.1371/journal.pone.0014282.t001
TIA-1 in Colorectal Cancer
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e14282protocols described above for the Test Group. Protein expression
was evaluated according to the scoring method described above by
an experienced gastro-intestinal pathologist (E.K.).
Flow cytometry analysis on fresh clinical specimens
Ten freshly excised clinical specimens were collected and tumor
fragments were minced and enzymatically digested in order to
obtain single cell suspensions. Cells were surface stained with
Fluorescein isothiocyanate (FITC)-labeled antibodies specific for
CD4, CD16 or CD66b (BD Pharmingen, San Diego, CA) or T-
cell-receptor (TCR)cd (Ebioscience, La Jolla, CA) molecules and
with APC-labeled antibodies specific for CD56 or Va24-Ja18
TCR (BD Pharmingen). After washing, cells were fixed with 2%
formaldehyde and subsequently permeabilized with 0.5% saponin
prior to intracellular staining with PE-labelled TIA-1-specific
antibodies (Immunotech, Marseille, France).
Study Design
The study design is outlined in Figure 1. Briefly, after exclusion
of MMR-deficient cases from the test cohort, univariate analysis
and multivariable survival time models were assessed to identify
the strongest independent prognostic protein markers and their
combined value. The independent prognostic value was subse-
quently evaluated on MMR-proficient colorectal cancer patients
from the Validation Group.
Statistical Analysis
In order to avoid bias from dichotomizing protein immunore-
activity, analyses were performed by examining scores 0, 1, 2 and
3 [11]. Kaplan-Meier curves were used to assess the influence of
protein expression on overall cancer-specific survival. Significance
was assessed in univariate analysis with the log-rank test. Cox
proportional-hazards models were used to test the simultaneous
influence on overall cancer-specific survival of protein expression
along with known prognostic factors and the assumption of
proportional hazards was tested by evaluating the log(-log(survi-
val)) versus log of survival time graphs. Rather than performing
split-group analysis, all multivariable models were validated and
95%CI obtained through 200 bootstrapped replications of the
data [12,13]. All tests were two-sided. Missing variables were
considered to be missing at random. No imputation was
performed rather case-wise deletion was carried out when
necessary. P-values are reported without adjustment for multiple
corrections [14]. All analyses were performed with SAS V9.1 (The
SAS Institute, Cary, NC, USA).
Results
Test Group
Cancer-specific survival analysis- Univariate (Figure
2). More favourable survival time was observed for patients
with higher numbers of CD3+ (p,0.001), CD4+ (p=0.029),
Figure 1. Overview of study design. (A) 1420 colorectal cancers were mounted onto tissue microarrays and immunostained for 13 protein
markers and mismatch repair (MMR) proteins. MMR-deficient tumors were excluded. (B) 221 colorectal cancers were mounted into a multiple-punch
tissue microarray and immunostained for independent prognostic factors identified in Test Group. MMR-deficient tumors were excluded from
analysis and validation of prognostic effects carried out on the remaining 209 patients.
doi:10.1371/journal.pone.0014282.g001
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GranzymeB+ (p,0.001), iNOS+ (p=0.035), MUM+1 (p=0.014),
PD1+ (p=0.034) and TIA-1+ TILs (p,0.001). Representative
photomicrographs of these protein markers and immunoreactive
cells are shown in Figure 3.
Cancer-specific survival analysis- Multivariable. Significant
markers were tested in two multivariable models. We first evaluated the
prognostic effect of the markers adjusting for the effects of age at
diagnosis, gender, pT, pN, tumor grade and vascular invasion. CD3
(n=945; 434 deaths; p=0.128), CD4 (n=1026; 491 deaths;
p=0.463), CD45RO (n=866; 401 deaths; p=0.181), FoxP3
(n=1091; 519 deaths; p=0.185), GranzymeB (n=987; 479 deaths;
p=0.091), iNOS (n=1023; 493 deaths; p=727), MUM1 (n=1082;
516 deaths; p=0.173), and PD1 (n=1096; 523 deaths; p=0.389) did
not show an effect on survival time after adjusting for these established
prognostic parameters. In contrast, CD8 (n=1019; 489 deaths;
p,0.001) and TIA-1 (n=1005; 481 deaths; p,0.001) maintained
their highly positive and significant impact on patient outcome.
In a second survival time model (Table 2) the effect of CD8 and
TIA-1 was again tested this time along with patient age at diagnosis,
gender, pT, pN, metastasis and adjuvant therapy. Results underline
a highlysignificantpositiveeffectoftwomarkers:(1)CD8+(n=292;
75 deaths; HR: 0.66 (95%CI: 0.64-0.68) and (2) TIA-1+ (n=290;
82 deaths; HR: 0.56 (95%CI: 0.5-0.6)).
Characterization of TIA-1-expressing cells. Given that
TIA-1 is hypothesized as a marker for activated CD8+ T-cells, we
verified the coexpression of TIA-1 on CD8+ T cells by flow
cytometry on tumor infiltrating lymphocytes (TILs) from 10 freshly
excised clinical specimens. Percentages of total TIA-1+ cells
ranged from 0.86 to 6.52 (mean: 3.761.6) (Figure 4A).
Costaining with markers specific for defined cell populations
confirmed that the major population of TIA-1+ cells is represented
by CD8+ T cells (5768%) followed by TCRcd cells (22610%)
and CD66b+ neutrophils (13612%). In contrast negligible
percentages of CD4+ T cells, macrophages (identified as CD16+
CD56- cells), NK cells (identified as CD56+ cells), and NK/T
cells, (expressing Va24-Ja18 TCR), were observed (Figure 4 B,
C). TIA-1 expression was detected on a majority of infiltrating
CD8+ cells (64622%), whereas the remaining fraction (35622%)
was TIA-1 negative (Figure 4C, D).
Phenotypic combinations of CD8/TIA-1. We next
analyzed the phenotypic frequencies of the 1019 colorectal
cancers with both evaluable CD8 and TIA-1 staining. Three
major phenotypes were observed: tumors negative for both CD8
(Score 0) and TIA-1 (Score 0) (n=223; 21.9%), tumors positive for
CD8 but negative for TIA-1 (n=366; 36%) and tumors positive
for both CD8 and TIA-1 (n=350; 34.3%). Only 80 tumors were
negative for CD8 and positive for TIA-1 (7.8%). Due to these
small numbers, the group of CD8 negative tumors was classified as
a single subgroup irrespective of TIA-1 expression.
Cancer-specific survival analysis of CD8+ TILs stratified
by TIA-1. Survival time differences were analyzed for the three
CD8/TIA-1 phenotypes in 998 patients for whom survival time
was also available. Overall, a significant difference in cancer-
specific survival times was noted between the three groups with
patients with higher amounts of CD8+/TIA-1+ TILs experiencing
the most favourable outcome, followed by CD8+/TIA-1- cases
and finally by CD8- patients (p,0.0001; Figure 5). We next
performed multivariable analysis including the prognostic factors
age, gender, pT, pN pM stage as well as post-operative therapy
and determined the added benefit of stratifying patients with
tumors with higher amounts of CD8+ TILs by TIA-1. Among
Figure 2. Bar graphs illustrating the hazard ratio and 95%CI for the prognostic effect of each biomarker. Highlighted markers are those
showing a significant association with prognosis.
doi:10.1371/journal.pone.0014282.g002
TIA-1 in Colorectal Cancer
PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e14282Figure 3. Representative immunostains for biomarkers with prognostic significance in the Test Group. A) CD3, B) CD4, C) CD8, D)
CD45RO, E) FoxP3, F) Granzyme B, G) iNOS, H) MUM1, I) PD1, J) TIA-1.
doi:10.1371/journal.pone.0014282.g003
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(95%CI: 0.8-0.9) was observed for those with simultaneous TIA-1-
positive tumors (p,0.001; Table 2). These results indicate that
the addition of TIA-1 in cases of CD8-positivity improves the risk
stratification for 35.6% (n=355) of patients.
Validation Group
An external validation set was analysed for CD8+ and TIA-1+
TILs. In this group of MMR-proficient colorectal cancer, only 7
patients had tumors with CD8+/TIA-1- TILs In univariable
analysis, survival time differences for patients with CD8+/TIA-1+
TILs were significantly higher compared to patients with absence
of CD8+ TILs (p,0.0001). Survival time differences between
patients with different CD8/TIA-1 phenotypes were evaluated in
multivariable analysis with pT stage, pN stage, pM and adjuvant
therapy. Among patients with CD8-positive tumors, TIA-1
positivity led to a relative risk of 0.79 (95%CI: 0.7-0.9) compared
to patients with TIA-1-negative cancers (p=0.006).
Table 2. Multiple Cox regression analysis showing the
independent prognostic effect of CD8, TIA-1 and of TIA-1
among CD8+ cases (all p-values ,0.001).
HR (95%CI)
CD8 alone TIA-1 alone
Effect of TIA-1
in CD8+ cases
Marker 0.66 (0.64-0.68) 0.57 (0.5-0.6) 0.89 (0.8-0.9)
Age (yrs) 1.03 (1.03-1.03) 1.03 (1.03-1.03) 1.05 (1.04-1.06)
Gender 0.72 (0.69-0.75) 0.64 (0.6-0.7) 0.56 (0.5-0.6)
pT 3.85 (3.51-4.23) 3.81 (3.5-4.1) 1.69 (4.1-5.3)
pN 3.01 (2.9-3.2) 2.24 (2.1-2.3) 2.56(2.4-2.8)
Metastasis 8.93 (8.5-9.4) 8.93 (8.5-9.4) 18.0 (16.6-20.0)
Post-operative
therapy
1.45 (1.4-1.5) 1.88 (1.8-1.9) 2.12 (2.0-2.3)
doi:10.1371/journal.pone.0014282.t002
Figure 4. TIA-1 expression on TILs. Single cell suspensions obtained from freshly excised tumor specimens (n=10)were surfacestained with FITC- or
APC-labeled antibodies specific for the indicated surface markers and intracellularly stained with PE-labeled anti-TIA-1 antibodies. A) Percentages of total
TIA-1+cellsB)PercentagesofCD8+cells,TCRcd cells, neutrophils (identified as CD66b+cells),CD4+cells, macrophages (identified as CD16+CD56-cells),NK
cells (CD16+ CD56+) and NKT cells (Va24-Ja18 TCR+) observed within gated TIA-1+ cells. C) Representative dot-plot illustrating co-expression of TIA-1 and
CD8molecules withingatedlymphocytesontotalcellsobtainedfromaclinicalspecimen.D)PercentagesofTIA-1+and TIA-1- cells within gated CD8+cells.
doi:10.1371/journal.pone.0014282.g004
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The novel findings of this study on 1406 MMR-proficient
colorectal cancer patients suggest first, that higher numbers of
TIA-1+ TILs represent a favourable and independent prognostic
parameter and second that in addition to CD8, TIA-1 improves
the prognostic stratification of patients by 35%.
Although the prognostic significance of abundant CD8+ TILs
has previously been established [3,5,15,16,17], this study goes one
step further to identify the marker TIA-1 as a highly relevant
prognostic parameter in colorectal cancer and particularly in
tumors with marked cytotoxic CD8+ TILs. TIA-1 is a cytoplasmic
granule-associated RNA binding protein reportedly expressed in
cells with cytolytic potential, including 50-60% of CD8+ T-
lymphocytes [18]. TIA-1 has been shown to be involved in Fas-
mediated apoptosis in a variety of human malignancies, and to
sensitize endothelial cells to pro-apoptotic stimuli while also
enhancing NK cell cytotoxic activity [19,20,21]. Our results are in
agreement with these findings. Here, we show that 64% of CD8+
TILs co-express TIA-1. Additionally, we identify a small
population of CD8- but TIA-1+ tumor infiltrating cells represent-
ing populations of TCRcd cells and neutrophils and to a lesser
extent CD4+ T cells, macrophages, NK cells, and NK/T cells.
Investigations on the clinical and prognostic implications of
TIA-1+ lymphocytes is mostly restricted to haematological
malignancies with both favourable and unfavourable effects
attributed to over-expression of this protein [22,23]. Only a
handful of studies have evaluated TIA-1 expression on TILs in
colorectal cancer, relating up-regulation to apoptosis and an
increased number of TIA-1+ TILs in MMR-deficient tumors
[24,25]. Interestingly, in our MMR-proficient cases, we could not
find any correlation between higher numbers of TIA-1+ cells and
tumor expression of the anti-apoptotic marker Bcl-2, pro-apoptotic
markers Apoptosis Activating Factor-1 (APAF-1) and Mammalian
Sterile20-like kinase 1 (MST-1), nor with p53 or the proliferation
marker Ki67 (data not shown). However, we not only report that
increased numbers of TIA-1+ TILs is strongly associated with an
improved clinical outcome, but represent an independent
prognostic factor, in test and validation study cohorts. Most
importantly, our results indicate that the effect of TIA-1 on
outcome is additive to CD8, a result which has implications for
35% of all patients. Hence, the significantly more favourable
outcome of patients with CD8+/TIA-1+ TILs compared to cases
with CD8+/TIA-1- TILs may be indicative of a more efficient
immunosurveillance by TILs with an activated and highly
cytotoxic potential.
Results of this study also identified several other types of TILs
within the tumor center as having a positive impact on prognosis,
for example FoxP3. The prognostic role of Tregs seems to vary
significantly by tumor type possibly indicating differential roles of
these cells in a tissue-dependent manner [26–28]. In colorectal
Figure 5. Kaplan-Meier survival curve shows the prognostic effect of CD8-negative, CD8+/TIA-1- and CD+8/TIA-1+ cells (Test Group).
doi:10.1371/journal.pone.0014282.g005
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high number of FoxP3 Tregs is a favourable prognostic factor for
disease-free and overall survival time [10,29,30]. However, this
effect, as highlighted here, does not appear to be independent of
CD8+.
Although our study may be limited by incomplete clinical
information in some cases, we could still confirm the independent
prognostic effect of TIA-1 and its modifying effect on CD8 in 500
patients with complete TNM and therapy information. The MMR
status was analysed by expression of protein markers MLH1,
MSH2 and MSH6 and only tumors with positivity in all three
markers were included in this analysis. These markers as well as
TIA-1 and CD8 are routinely used in diagnostic pathology, the
latter two for T-cell lineage determination and subtyping of
lymphomas thus supporting their value as reliable research tools as
well [31,32]. The use of TMAs often raises the concern that
protein expression of heterogeneous tumors is not adequately
represented using this technique. However, in daily diagnostic
work, the occurrence of TILs is known to be quite homogeneous
and while one tumor punch was sampled in the Test Group, the
additional inclusion of a validation cohort with an average of 4
tumor punches per tumor sampled should minimize bias from
possible tumor heterogeneity [33]. Furthermore, our study benefits
from the use of test and validation cohorts, the latter representing
an independent, external validation subset on which protein
markers were assessed by multiple independent pathologists, thus
further confirming the reproducibility of the CD8/TIA-1 scoring
system and effect on outcome.
To summarize, TIA-1 is a robust prognostic immunological
biomarker that contributes to clinical outcome in patients with
MMR-proficient colorectal cancers independently of TNM stage
and adjuvant therapy. The combined analysis of CD8/TIA-1
identifies a large subgroup of patients, who benefit from improved
risk stratification, which should aid to tailor more individual
clinical management for patients with colorectal cancer patient,
while providing a new potential avenue of investigation for the
development of targeted immunotherapy.
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